AuM
Pre-clinical- Indications
- Alzheimer's disease, Huntington's disease, Traumatic brain injury, Autism spectrum disorders, Substance use disorder
Company intelligence / Profile preview
NeurANO Bioscience
La Jolla, California, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
NeurANO Bioscience is developing nanotherapeutics that are designed to be large enough to be deflected from narrow synaptic clefts while small enough to diffuse through the brain to block pathological activity of glutamate by targeting extrasynaptic NMDA receptors. The company has received multiple SBIR Phase I grants for various neurological indications.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Nanotherapeuticssmall molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NeurANO Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeurANO Bioscience.